Search

Across jurisdictions, government and health insurance providers hold a large amount of data from patient interactions with the healthcare system. We aimed to develop a machine learning-based model for predicting adverse outcomes due to diabetes complications using administrative health data from the single-payer health system in Ontario, Canada. A Gradient Boosting Decision Tree model was trained on data from 1,029,366 patients, validated on 272,864 patients, and tested on 265,406 patients. Discrimination was assessed using the AUC statistic and calibration was assessed visually using calibration plots overall and across population subgroups. Our model predicting three-year risk of adverse outcomes due to diabetes complications (hyper/hypoglycemia, tissue infection, retinopathy, cardiovascular events, amputation) included 700 features from multiple diverse data sources and had strong discrimination (average test AUC = 77.7, range 77.7-77.9). Through the design and validation of a high-performance model to predict diabetes complications adverse outcomes at the population level, we demonstrate the potential of machine learning and administrative health data to inform health planning and healthcare resource allocation for diabetes management.

The increasing prevalence of type 2 diabetes mellitus (T2DM) and its associated health complications highlight the need to develop predictive models for early diagnosis and intervention. While many artificial intelligence (AI) models for T2DM risk prediction have emerged, a comprehensive review of their advancements and challenges is currently lacking. This scoping review maps out the existing literature on AI-based models for T2DM prediction, adhering to the PRISMA extension for Scoping Reviews guidelines. A systematic search of longitudinal studies was conducted across four databases, including PubMed, Scopus, IEEE-Xplore, and Google Scholar. Forty studies that met our inclusion criteria were reviewed. Classical machine learning (ML) models dominated these studies, with electronic health records (EHR) being the predominant data modality, followed by multi-omics, while medical imaging was the least utilized. Most studies employed unimodal AI models, with only ten adopting multimodal approaches. Both unimodal and multimodal models showed promising results, with the latter being superior. Almost all studies performed internal validation, but only five conducted external validation. Most studies utilized the area under the curve (AUC) for discrimination measures. Notably, only five studies provided insights into the calibration of their models. Half of the studies used interpretability methods to identify key risk predictors revealed by their models. Although a minority highlighted novel risk predictors, the majority reported commonly known ones. Our review provides valuable insights into the current state and limitations of AI-based models for T2DM prediction and highlights the challenges associated with their development and clinical integration. [ABSTRACT FROM AUTHOR]

Digital biomarkers can radically transform the standard of care for chronic conditions that are complex to manage. In this work, we propose a scalable computational framework for discovering digital biomarkers of glycemic control. As a feasibility study, we leveraged over 79,000 days of digital data to define objective features, model the impact of each feature, classify glycemic control, and identify the most impactful digital biomarkers. Our research shows that glycemic control varies by age group, and was worse in the youngest population of subjects between the ages of 2–14. In addition, digital biomarkers like prior-day time above range and prior-day time in range, as well as total daily bolus and total daily basal were most predictive of impending glycemic control. With a combination of the top-ranked digital biomarkers, we achieved an average F1 score of 82.4% and 89.7% for classifying next-day glycemic control across two unique datasets. [ABSTRACT FROM AUTHOR]

Machine learning (ML) is a rapidly advancing field with increasing utility in health care. We conducted a systematic review and critical appraisal of ML applications in vascular surgery. MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to March 1, 2021. Study screening, data extraction, and quality assessment were performed by two independent reviewers, with a third author resolving discrepancies. All original studies reporting ML applications in vascular surgery were included. Publication trends, disease conditions, methodologies, and outcomes were summarized. Critical appraisal was conducted using the PROBAST risk-of-bias and TRIPOD reporting adherence tools. We included 212 studies from a pool of 2235 unique articles. ML techniques were used for diagnosis, prognosis, and image segmentation in carotid stenosis, aortic aneurysm/dissection, peripheral artery disease, diabetic foot ulcer, venous disease, and renal artery stenosis. The number of publications on ML in vascular surgery increased from 1 (1991–1996) to 118 (2016–2021). Most studies were retrospective and single center, with no randomized controlled trials. The median area under the receiver operating characteristic curve (AUROC) was 0.88 (range 0.61–1.00), with 79.5% [62/78] studies reporting AUROC ≥ 0.80. Out of 22 studies comparing ML techniques to existing prediction tools, clinicians, or traditional regression models, 20 performed better and 2 performed similarly. Overall, 94.8% (201/212) studies had high risk-of-bias and adherence to reporting standards was poor with a rate of 41.4%. Despite improvements over time, study quality and reporting remain inadequate. Future studies should consider standardized tools such as PROBAST and TRIPOD to improve study quality and clinical applicability. [ABSTRACT FROM AUTHOR]